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Abstract
In this study we propose a deformation-based framework to jointly model the influence of aging and Alzheimer’s
disease (AD) on the brain morphological evolution. Our approach combines a spatio-temporal description
of both processes into a generative model. A reference morphology is deformed along specific trajectories to
match subject specific morphologies. It is used to define two imaging progression markers: 1) a morphological
age and 2) a disease score. These markers can be computed regionally in any brain region.
The approach is evaluated on brain structural magnetic resonance images (MRI) from the ADNI database.
The model is first estimated on a control population using longitudinal data, then, for each testing subject, the
markers are computed cross-sectionally for each acquisition. The longitudinal evolution of these markers is
then studied in relation with the clinical diagnosis of the subjects and used to generate possible morphological
evolutions.
In the model, the morphological changes associated with normal aging are mainly found around the
ventricles, while the Alzheimer’s disease specific changes are located in the temporal lobe and the hippocampal
area. The statistical analysis of these markers highlights differences between clinical conditions even though
the inter-subject variability is quite high. The model is also generative since it can be used to simulate
plausible morphological trajectories associated with the disease.
Our method quantifies two interpretable scalar imaging biomarkers assessing respectively the effects of
aging and disease on brain morphology, at the individual and population level. These markers confirm the
presence of an accelerated apparent aging component in Alzheimer’s patients but they also highlight specific
morphological changes that can help discriminate clinical conditions even in prodromal stages. More generally,
the joint modeling of normal and pathological evolutions shows promising results to describe age-related brain
diseases over long time scales.
Keywords: aging, Alzheimer’s disease, brain morphology, deformations, spatio-temporal model, imaging
biomarkers.
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1 Introduction
Age-related diseases are a growing public health concern with the aging of the population. For this reason,
a precise description of aging would be useful to predict and describe the evolution of these diseases. In
complement to the chronological age, i.e. the time elapsed since birth, one would like to estimate a biological
age that reflects the current physiological, functional or structural status of an organ relatively to the aging
changes. However there is no unified way to describe aging in a clinical context since aging is a complex
process which affects every part of the body with specific mechanisms and specific rate. As a consequence
multiple theories of aging have been proposed [Medvedev, 1990], leading to the definition of surrogate age
variables based on the quantification of biological changes.
1.1 Modeling brain morphological aging
In this paper we focus on the aging of the brain based on the study of its shape evolution. The brain is not
exempt from aging and a decline of cognitive processing speed, working memory, inhibitory function, and
long-term memory is generally observed. This decline has been associated with neural activity changes [Park
and Reuter-Lorenz, 2009] and it was also shown to be directly correlated with structural changes such as
brain atrophy, cortex thinning and decrease of white matter integrity [Rosen et al., 2003, Rodrigue and Raz,
2004].
The normal brain morphology has been studied in image-based studies from the development stage to
the most advanced ages. Measurements of brain structures (volumes, cortical thickness, etc.) have been
performed for wide age ranges and the statistical analysis of the evolution of these measurements helps in
providing an initial understanding of the normal brain shape evolution across life span [Good et al., 2001,
Long et al., 2012]. These descriptions have been used to estimate models characterizing brain aging in order
to highlight differences across brain areas [Hutton et al., 2009, Sowell et al., 2003]. The inverse problem,
i.e. how to associate an age to a brain image, was also addressed. Models have been designed to estimate
the chronological age [Cole et al., 2018] from an image but they can also be used to characterize abnormal
evolutions. For instance, a mean brain age gap estimate was highlighted for Alzheimer’s patients [Franke
et al., 2010]. More generally, these surrogate brain age estimates have been associated with an increase of
risk factors for several age-related disorders such as cardio-vascular diseases [DeCarli et al., 2005, van Velsen
et al., 2013]. In a longitudinal setting, a brain age measurement could be used to compare the evolution of
several clinical conditions (see Figure 1).
1.2 Disease progression modeling
Brain aging is often associated with the development of neurodegenerative pathologies. For example, it
is estimated that one in three people over 85 have Alzheimer’s disease (AD), the most common form of
dementia [Alzheimer’s Association and others, 2017]. This disease comes with its own specific apparent brain
morphological changes [Ohnishi et al., 2001] and computer-aided diagnosis techniques using neuroimaging
features have shown promising results to classify and to predict clinical evolutions [Davatzikos et al., 2009,
Klöppel et al., 2012, Schmitter et al., 2015]. Longitudinal studies provide us with multiple acquisitions at
different times for every subject but the disease affects patients over several decades, starting even before the
first symptoms occur, and few studies follow a significant number of subjects over such long times. Progression
models have been developed to describe the global evolution and to put in relation the individual trajectories
that could only be observed a limited number of times. They have been used to model the progression of
biomarkers [Fonteijn et al., 2012, Donohue et al., 2014] but also directly brain shape [Cury et al., 2016] or
spatio-temporal patterns in brain images [Koval et al., 2017, Schiratti et al., 2017]. These models produce
good representations of the disease progression and can combine a variety of available biomarkers for patient
monitoring [Bilgel et al., 2016, Lorenzi et al., 2019].
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Figure 1: Schematic representation of two evolutions relative to an hypothetical morphological age reflecting
the structural status of the brain relative to the aging process.
1.3 Toward a joint model of brain aging and disease progression
The morphological aging of the brain and disease progression have generally been modeled independently.
However we know that the structural features used in diagnosis (e.g cortical thickness or atrophy patterns)
are also generally related to age. Indeed aging and neurodegenerative diseases involve intertwined processes
with entangled consequences. Surrogate age measurements have been used to support the disease charac-
terization [Franke and Gaser, 2012] or to put aside the aging part in order to focus on the disease specific
changes. Lorenzi et al. [2015] proposed to model the normal aging evolution to separate the contribution of
aging from a remainder that is not explicitly modeled. This remainder is then used to describe the patholog-
ical evolution. However, this method does not propose an intrinsic model of the disease progression making
it difficult to describe and to characterize disease specific changes.
In this study, we propose a generative model of the brain morphological evolution that jointly takes into
account the normal aging and the disease effects. Our model is based on the approach proposed by Lorenzi
et al. [2015] and gives a deformation-based description of subject trajectories. It extends the original ap-
proach by explicitly modeling the disease specific brain morphological evolution. In addition to the apparent
morphological age computed in the proposed approach, it allows us to get a disease score, thus providing two
morphological imaging biomarkers accounting for the progression of the two main ongoing processes: normal
aging and Alzheimer’s disease. These biomarkers are estimated cross-sectionnally from a single structural
MRI but the model estimation exploits longitudinal data to match as accurately as possible the morphological
evolution of the subjects.
We introduce in section 2 the generative model used to represent the brain morphology. Section 3 focuses
on the estimation of the model parameters and on the inverse problem solved to compute the morphological
age and the disease score of a subject. Experimental results are then presented in section 4 in order to
evaluate our model and parameter estimation procedure. We illustrate how the model helps to describe
the evolution of subjects at different disease stages using the ADNI database. Then we show how the two
proposed markers can help to follow the evolution of elderly patients. Finally, limitations and perspectives
are discussed in section 5.
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2 Definition of the generative model
In the sequel, we quantify differences between morphologies by spatial deformations that can be estimated
from magnetic resonance images (MRI) through non-linear image registration. A deformation represents
either a morphological difference between the anatomies of two subjects or a longitudinal evolution of one
subject-specific anatomy. Therefore deformation based frameworks are well suited to define a parametric
model of the morphology. Our approach involves a population template morphology which is parametrized
by two progression markers: the morphological age and the disease score.
In section 2.1, we expose the main ideas behind the definition of our reference parametric space. Then in
section 2.2, we explain how the morphological evolutions are modeled in our framework. Finally in section 2.3,
we show how we use the deformation framework to model individual morphologies relatively to this reference.
2.1 A space of reference morphologies
In deformation based morphometry, a single morphology is classically used to approximate and represent
a population. For a set of images {Ik}, we define a common reference image T0, called template. The
difference of morphology between the subject k and the template is modeled with a spatial deformation φk
and an intensity noise k is added in the subject space accounting for local intensity variability. Therefore
the images are modeled as follows:
Ik = T0 ◦ φk + k.
In our approach, we want to take into account two major processes that affect the brain morphology over
time: the normal aging and the disease evolution. To do so, we model the effects of these processes on the
template using a deformation Φ parametrized by two variables that measure the progress of each process:
the morphological age λMA and the disease score λDS . The two variables λMA and λDS can be seen as
time variables and are scaled to correspond to years of standard evolution. In this model, T0 ◦Φ(λMA, λDS)
represents the template morphology after λMA years of normal aging and λDS years of normalized disease
progression.
In the ideal case, the morphological age is equal to the chronological age. Therefore, T0 ◦Φ(t, 0) represents
the morphology of a t years old healthy subject. Similarly T0 ◦Φ(t, t′) would be the typical morphology of a
AD patient of age t with a disease duration of t′ years. If one is able to associate an age λ0 to the image T0,
and assumes that this is the image of a healthy subject, then it is natural to enforce Φ(λ0, 0) = Id.
The parametric subspace of images generated like this will be used as a reference:
T = {T0 ◦ Φ(λMA, λDS) for λMA, λDS ∈ R} . (1)
An initial model of the subject images is then:
Ik = T0 ◦ Φ(λkMA, λkDS) ◦ φk + k,
where λkMA and λ
k
DS are the subject morphological age and disease score, while φk encodes differences specific
to the subject morphology. Of course multiple options are available to combine the longitudinal deformation
Φ with the subject specific changes φk. Here we write this operation as a right-composition but this choice
will be discussed in section 2.2 and a similar but symmetrical operation will later be used.
Also, in the reference space, trajectories parametrized by time t 7→ T0 ◦ Φ(λMA(t), λDS(t)) give possible
morphological evolutions where the morphological age and the disease score can be seen as reparametrization
of time. In particular, it defines two archetypal trajectories (i.e. ideal models of evolution): the normal aging
template trajectory t 7→ T0 ◦ Φ(t, 0) and the disease specific template trajectory t 7→ T0 ◦ Φ(λ0, t).
Here, we assume that each progression of the two major processes (aging and disease) can be described
with only one parameter. This implies that the evolution of healthy aging is similar for each subject,
following the normal aging template trajectory, even if the speed of aging may vary from one subject to the
other. Similarly, the disease progression is described using a single trajectory and we combine both template
trajectories to model pathological evolutions.
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2.2 Modeling the morphological evolution of the template
In a simplified approach, the template trajectories are assumed to be geodesics in an appropriate deformation
space. Geodesics define continuous paths that can be easily parametrized and constrained to allow regularity
in time. They can be used to interpolate between two anatomies or to approximate more complex trajecto-
ries [Christensen et al., 1994, Wang et al., 2007]. In this paper, we use the stationary velocity field (SVF)
framework [Arsigny et al., 2006] for its ability to describe complex and realistic diffeomorphic (smooth and
invertible) brain deformations in a straightforward manner [Lorenzi et al., 2013]. In this framework, the
observed anatomical changes are encoded by diffeomorphisms which are parametrized with the flow of SVFs.
Within this setting, the metric between deformations is not chosen a priori even if we need a regularization
criterion for the registration. To compute a deformation φ we integrate trajectories along the vector field v
for a unit of time.
φ(x) = φ1(x) =
∫ 1
0
v(φt(x))dt with φ0 = Id.
This relationship is denoted as the group exponential map φ = Exp(v).
By writing Φ(λMA, λDS) = Exp(λMAvA +λDSvD), we propose a linear model in the SVF space (i.e. the
space of the parameter of the deformations) parametrized by two SVFs vA and vD. In particular, the two
template trajectories are then separately parametrized: vA controls the normal aging template trajectory
and vD the disease specific template trajectory.
For each subject, the processes are meant to be intertwined and this can be modeled in different ways
depending on the parametrization of the trajectories, for instance a right or a left composition. The proposed
linear combination of the parameters provides us a middle ground. Indeed in the SVF setting, the rela-
tionship between composition and the linear combination of SVFs is given by the Baker-Campbell-Hausdorff
formula [Bossa et al., 2007] and the linear combination of the SVFs is equivalent to alternate between right
and left composition with infinitesimal steps.
To sum up, the longitudinal deformation Φ modeling the effects of aging and the disease on a reference
morphology T0 is parametrized by two SVFs: vA and vD. This ideal model generates a surface T of possible
images describing the evolution of the template morphology:
T = {T0 ◦ Exp(λMAvA + λDSvD) for λMA, λDS ∈ R} . (2)
2.3 Individual morphological variability and generative model
An individual image is modeled as follows:
Ik = T0 ◦ Exp((λkMA − λ0)vA + λkDSvD) ◦ φk + k, (3)
where the choice of the intensity noise k is implicitly related to the registration similarity metric. To specify
the constraint on φk, we define a subject specific residual SVF wkr (r stands for residual) such that:
Exp((λkMA − λ0)vA + λkDSvD) ◦ φk = Exp((λkMA − λ0)vA + λkDSvD + wkr ).
In this formula, Exp(wkr ) is approximately equal to φk given the first order of the BCH equation between
composition and linear combination of SVFs. Moreover, we wish to have the subject specific deformation to
encode what cannot be described using the template trajectories. That is why we impose wkr to be orthogonal
to both vA and vD.
As we can see in Figure 2, the model parametrized by vA and vD allows us to characterize the subject
morphology with two scalar variables, the morphological age λkMA and the disease score λ
k
DS , and a SVF
wkr for the subject-specific part. The orthogonality constraint makes the description of the subject uniquely
defined. We denote by wk the subject-to-template deformation SVF:
wk = (λkMA − λ0)vA + λkDSvD + wkr . (4)
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Figure 2: Our two-trajectory model. The template image T0, the normal aging template trajectory
parametrized by vA and the disease specific template trajectory parametrized by vD define a subspace of
possible morphologies of reference. An individual morphology is characterized by a morphological age λkMA,
a disease score λkDS , and an SVF w
k
r modeling the subject-specific part. Each image can be projected onto
the template subspace T using a decomposition of the deformation between the image and the template T0.
3 Estimation of the model parameters
The model parameters are of two kinds: the population parameters (T0, vA and vD) and the subjects
parameters (λkMA, λ
k
DS and w
k
r ). To tackle this joint estimation problem in a computationally efficient way,
several assumptions are made:
1. When available, the longitudinal evolution in the template space can be approximated by the trans-
ported deformation estimated in the subject space. Parallel transport algorithms are commonly used
in the geometrical analysis of longitudinal data. The use of geodesic parallelograms is in general an
efficient way to bring individual trajectories in a common reference space [Lorenzi and Pennec, 2013].
In practice, it allows us to work only with intra-subject deformation to estimate the model population
parameters. It simplifies the optimization and is also more stable as the intra-subject variability is in
general smaller than the inter-subject one.
2. We also assume, while estimating the population parameters, that the aging speed and the disease
progression speed are constant for all the subjects in the training set.
3. Intra-subject deformations are relatively small and smooth. Consequently, the registration regular-
ization has less impact on the estimated deformation. This consideration allows us to estimate these
longitudinal evolutions independently of the population model.
These assumptions allow us to efficiently decompose the problem of the parameter estimation. First,
subjects with longitudinal data are processed independently and the intra-subject evolutions are modeled in
the subject space. Then the population parameters (T0, vA and vD) are estimated using only intra-subject
longitudinal evolutions. Finally, the subjects’ parameters are estimated.
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3.1 Estimation of the template trajectories vA and vD in a given template space
In this section we suppose that we know T0 and that we can compute the subject-to-template deformation
wk for a reference time point. We also consider that we have longitudinal data for every subject.
First we address the inverse problem of estimating the intra-subject evolution parameters with the frame-
work proposed by Hadj-Hamou et al. [2016]. Images are preprocessed, rigidly aligned to the MNI-152 template
and then longitudinally registered. Intra-subject deformations between follow-up images and the baseline im-
age are computed using non-linear registration. The resulting intra-subject model in the subject’s space is
estimated using ordinary least square regression in the tangent space of SVFs. It is equivalent to the as-
sumption that the deformation noises are centered, uncorrelated and have equal variance in the space of
SVFs.
Then for a given template T0 and subject-to-template deformation wk, the intra-subject model can be
transported using parallel transport in the template space to get vk. This deformation can be decomposed
along the template trajectories giving a morphological aging rate (noted skMA), a disease progression rate
(noted skDS) and an orthogonal component (noted v
k
r ):
vk = skMAvA + s
k
DSvD + v
k
r .
These progression rates are strongly related to the evolution of the morphological age and of the disease
score (in a ideal euclidean case skMA = dλ
k
MA/dt and s
k
DS = dλ
k
DS/dt) and they will be used to normalize
the speed of evolution. The estimation is done on two groups of subjects: a group Gh composed by healthy
subjects and a group Gad composed by patients diagnosed with AD. We assume that each healthy subject
of Gh is aging at normal speed skMA = 1,∀k ∈ Gh and does not have any evolution toward the disease
skDS = 0,∀k ∈ Gh. Similarly, each patient of Gad has a normal morphological aging rate skMA = 1,∀k ∈ Gad
and a constant unit disease progression rate skDS = 1,∀k ∈ Gad. Finally the subject specific components are
assumed to be centered, uncorrelated and to have a fixed variance. The maximum likelihood problem writes:
min
vA,vD
∑
k∈Gh
‖vk − vA‖2 +
∑
k∈Gad
‖vk − vA − vD‖2. (5)
The solution of the optimization problem is explicit:
vˆA =
1
|Gh|
∑
k∈Gh
vk, (6)
vˆD =
(
1
|Gad|
∑
k∈Gad
vk
)
− vˆA. (7)
We should however note that ‖vˆA‖ (resp. ‖vˆD‖) is a biased estimator of ‖vA‖ (resp. ‖vD‖). We detail the
bias estimation in the Appendix 6.2.
3.2 Estimation of the template morphology T0
The population specific template morphology is computed using the algorithm proposed by Guimond et al.
[2000] by alternating the registration of subject images to the template and the recomputation of the template
intensities. However, in our approach, the subjects’ images do not need to be registered to T0 directly but
to their projection on the template space. To tackle this problem, we propose an iterative procedure where
we register the image to its current projection on the reference space. Algorithm 1 details the procedure
with simplified notations in the general case where w parametrizes the deformation between the image I and
T . The reference linear subspace of SVF is denoted T and w is decomposed accordingly w = wt + wr with
wt ∈ T , wr ∈ T ⊥. The registration regularization should only be applied to the residual part wr. In the
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Data: an image I, a template image T and linear space of SVF T
Result: two SVFs: wt ∈ T , wr ∈ T ⊥
wt = 0 ;
repeat
wr = registration(T ◦ Exp(wt), I) ;
wt = wt + projT (wr);
until wr ⊥ T ;
Algorithm 1: Iterative registration algorithm
Data: a set of images (Ik) and a linear space of SVF T
Result: a template image T , a set of pairs of SVFs (wkt , wkr )
wkt = 0 for all k;
initialize T ;
repeat
wkr = registration(T ◦ Exp(wkt ), Ik) for all k;
u = mean(wkr ) ;
T = mean(Ik ◦ Exp(−wkr + u)) ;
wkt = w
k
t + projT (wkr − u) for all k;
until convergence;
Algorithm 2: Iterative template space estimation algorithm
context of the LCC-demons registration algorithm, it boils down to the following minimization problem [see
Lorenzi et al., 2013]:
min
wt∈T ,wr∈T ⊥,w′
Sim(I, T,Exp(wt + wr)) + Dist(wr, w′) + Reg(w′).
The idea is to alternate between the optimization and the projection on the constraints.
Since we do not have any theoretical guarantee on the convergence of the algorithm, the stability and the
convergence will be evaluated empirically. As the template estimation also involves iterative search, we can
combine both algorithms for a faster optimization. The projection coordinates are kept from one iteration to
the next and the images are registered to their estimated projections in the template space. The deformation
update u is then computed and finally the new atlas image T and the estimated projections are updated (see
Algorithm 2).
In this work, the intra-subject models are transported to the template space to update the template
trajectories parametrizing T at each iteration (using the approach described in the previous section 3.1). T
is initialized using the MNI-152 template and the convergence is manually assessed comparing the template
for successive iterations. At convergence, we obtain the template image T0 and both template trajectories
vA and vD.
3.3 Estimation of the subject’s parameters
When the population parameters are learned, the estimation of the individual parameters for a new subject is
relatively simple. The deformation wk is computed by registration between a subject image and the template
using Algorithm 1, and then linearly decomposed, wk = (λkMA−λ0)vA+λkDSvD+wkr , by solving the following
linear system:
wk · vA = ‖vA‖2(λkMA − λ0) + vD · vAλkDS , (8)
wk · vD = vD · vA(λkMA − λ0) + ‖vD‖2λkDS . (9)
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In practice, the estimation is not exact because we work with the noisy estimators vˆA and vˆD. The linear
decomposition can also be computed locally or by using any voxel weighting scheme for the scalar product.
When longitudinal data is available, this estimation is independently done for each time point.
4 Results
4.1 Experiments with synthetic data
We first evaluate our approach using synthetic data in order to assess the accuracy and the reproducibility of
the biomarkers estimation. Realistic longitudinal MRIs are simulated using the software proposed by Khanal
et al. [2016]. The simulation algorithm relies on a biophysical model of brain deformation and can be used
to generate longitudinal evolutions with specific atrophy patterns. In this context, local atrophy is measured
by the divergence of the stationary velocity field.
4.1.1 Simulated dataset
In this controlled experiments we choose to simulate two populations that are characterized by their atrophy
patterns and that respectively emulate healthy controls and AD patients. Atrophy of the aging brain and
the effect of AD have been extensively studied [Pini et al., 2016] and the atrophy measurements may vary
depending on the methodology and the population studied. In this experiment, we choose to prescribe
piecewise-constant atrophy map with constant value in brain areas delimited by the segmentation provided
by FreeSurfer [Fischl et al., 2002]. For every subject, the atrophy value of a region is sampled around a
fixed population mean with an additive Gaussian noise of relative standard deviation of 5% . The healthy
population is designed to have a small atrophy in the whole brain while the patients have a stronger atrophy
especially in the hippocampal areas and the temporal poles. The means are chosen to give the order of
magnitude of a one year evolution accordingly to what was reported in Fjell et al. [2010] for healthy aging
and in Carmichael et al. [2013], with an additional scaling for the pathological evolution. We detail the exact
regional values in Table 2 in the appendix (see 6.1).
Structural MRIs of 40 healthy subjects from the ADNI database are taken as input to the simulations.
For every subject, deformations are simulated for both pathological and healthy settings. The deformation
extrapolated 5 times is then applied to the original image in order to simulate 5 years long evolutions. We
then have two matched populations of 40 pairs of images.
4.1.2 Model estimation
Individual longitudinal deformations are computed using registration, and the reference anatomy and the
template trajectories are built using our framework. The divergence fields associated with these template
trajectories can be compared to the prescribed atrophy. Figure 3 shows the average atrophy maps in the
estimated template anatomy.
The estimated atrophy patterns are smoothed versions of the simulated ground truth. This effect was
already observed [Khanal et al., 2016]. First of all, the registration algorithm is unaware of the underlying
simulation model and is unable to localize precisely the atrophy in homogeneous areas. Moreover, the spatial
regularization of the registration and the parametrisation using SVFs also contribute to the smoothness of the
estimated atrophy patterns. This is particularly visible in small (hippocampus) or thin regions (cortex). We
therefore have a consistent bias when the atrophy measurements are integrated over the regions (see Figure 14
in appendix). Indeed, the local atrophy is affected by neighboring regions evolving in the opposite direction
(the ventricles or the CSF for example). However, we can see that the ratio between the pathological and
healthy cases is conserved in every region. It was already noted that quantitative estimation using registration
can be biased but can be more reproducible than the segmentation based approaches [Hadj-Hamou, 2016,
Cash et al., 2015].
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(a) Healthy evolution (b) Pathological evolution
relative volume change (year−1)
Figure 3: Simulated and estimated atrophy patterns in the template space. Top row: mean in the template
space of the prescribed atrophy maps. Bottom row: atrophy maps estimated from the simulated images.
Left: healthy simulations. Right: pathological simulations. The estimations are smoother but qualitatively
similar to simulated maps.
4.1.3 Imaging biomarkers estimation
The morphological age and the disease score were computed for each image. By construction there is no
difference at t=0 (exactly the same images in the two groups). We compare the simulated differences at t=5
and the evolution of the cross-sectional assessments for each subject (see Figure 4a).
In this experiment, the initial anatomical variability is important, indeed the standard deviation at t=0
is equal to 48 years for MA(0) and 24 years for DS(0). At t=5, a difference is visible for the disease score but
it is still diluted in the inter-subject variability. It is also possible to extrapolate the evolution to determine
how many years of evolution are needed in order to get a significant difference between the healthy and the
disease groups. For a significance level of 0.05, the disease score would be significantly discriminant after 13
years of evolution. This figure for synthetic data highlights the slow time-pace of the disease and the interest
in modeling and extrapolating the evolutions.
Looking at the evolution of these cross-sectional biomarkers in Figure 4b), we see that the measures
are relatively stable despite the large inter-subject variability and that the difference measured between two
different time points gives a good estimate of the longitudinal evolution. In practice the estimations are
slightly biased, for example the increase of morphological age ∆MA = MA(5) −MA(0) is expected to be
equal to 5 for both populations while the the mean of the estimation is equal to 3.92 for the healthy group
and to 3.57 for the patients group. More importantly, the standard deviation is small in comparison to the
standard deviation of the cross-sectional measurement (σ∆MA = 1.13 while σMA(0) = 47.8). For the change
of disease score ∆DS, the mean is equal to −0.6 for the healthy group and 2.8 for the patients group and it
approximates the ideal expected values (respectively 0 and 5). The variance is also very small with respect to
the cross-sectional one. In particular the difference between healthy and diseased subjects is clearly observed
for the longitudinal evolution: the difference between the means is equal to 3.2 standard deviation for ∆DS.
To summarize, the cross-sectional measurement gives a relatively stable assessment of the aging and disease
progression and the markers’ evolution is strongly associated with the clinical diagnosis. Our generative
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Figure 4: Evolution of the imaging biomarkers estimated on simulated data. MA=morphological age,
DS=disease score. The longitudinal evolutions ∆MA and ∆DS are the differences between the two cross-
sectional assessments i.e. ∆MA = MA(5) - MA(0). The star indicates that the difference between the
healthy and the diseased subjects is significant (p-value < 0.05) for the unpaired t-test. By construction
there is no difference between the two populations at t=0. The changes are generally underestimated but
the longitudinal evolutions show the stability of the estimation despite a strong inter-subject variability.
model is able to explain most of the independently simulated changes.
4.2 Experiments on ADNI data
Longitudinal T1 sequences were obtained from the Alzheimer’s Disease National Initiative (ADNI) database.
The ADNI was launched in 2003 with the primary goal to test whether magnetic resonance imaging (MRI),
positron emission tomography (PET), other biological markers, and clinical and neuropsychological assess-
ment could be combined to measure the progression of mild cognitive impairment and early Alzheimer’s
disease1. Subjects are classified according to the evolution of their cognitive diagnosis. Three diagnoses
are possible at each time point: normal, mild cognitive impairment (MCI) and Alzheimer’s disease. The
subjects are also sub-classified according to the positivity of the beta-amyloid 1-42. We then have 6 distinct
sub-groups: CN- (cognitively normal with negative Aβ), CN+ (cognitively normal with positive Aβ), MCIs-
(MCI stable during the study time-window with negative Aβ), MCIs+ (MCI stable with positive Aβ), MCIc
(MCI converter to AD) and AD (diagnosed with Alzheimer’s disease starting from the beginning). The
table 1 sums up the demographic description of the population.
We estimate our template morphology and the template trajectories on a subset of subjects. In order to
form this training set, we randomly selected 30 subjects from the CN- group and 30 from the AD group. To
reduce the variability associated with the estimation of the model, these subjects were selected among the
ones with strictly more than one followup acquisitions. In the following we distinguish between the training
set of 30+30 subjects used to build the model and the remaining testing set (with in particular 78 CN-
subjects and 173 AD subjects).
1see www.adni-info.org for more information.
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group CN- CN+ MCIs- MCIs+ MCIc AD
Number of subjects 108 69 96 120 228 203
Age at baseline 73.4 (5.6) 74.5 (6.5) 71.1 (7.7) 73.5 (6.6) 73.8 (7.1) 74.5 (7.7)
Gender (female) 47.2% 56.5% 47.9% 37.5% 41.7% 48.3%
Education (years) 16.4 (2.6) 16.2 (2.7) 16.2 (2.8) 16.4 (2.7) 16.0 (2.9) 15.0 (2.9)
ADAS13 at baseline 9.0 (4.0) 8.6 (5.0) 12.0 (4.9) 14.0 (5.4) 19.9 (6.7) 31.4 (7.3)
Table 1: Socio-demographic and clinical information of the study cohort. Standard deviations are shown in
parentheses.
4.2.1 Estimation of the normal aging and the disease-specific template trajectories
The template anatomy is an average of the healthy subjects anatomies, so its age corresponds to the mean
group age λ0 = 73.46 y.o. The result of the estimation is shown in Figure 5. The estimated normal aging
template trajectory is characterized mainly by ventricular expansion caused by the atrophy of the surrounding
regions. Disease specific changes are widespread in the brain with a strong emphasis on the temporal areas.
(a) Normal aging template trajectory (b) Disease specific template trajectory
(mm · year−1)
Figure 5: Template image and SVFs parametrizing the two template trajectories SVFs. Left: normal aging
trajectory vA showing a ventricular expansion related to a global atrophy. Right: disease specific trajectory
vD showing specific patterns, especially in the temporal lobes around the hippocampi areas. The color
encodes the amplitude of the velocity at each position.
The local atrophy can be measured by the divergence of the velocity field. The atrophy associated with
each template trajectory is shown in Figure 6. For the normal aging, we see a well spread and mild atrophy
pattern in the whole brain. The disease specific atrophy is particularly strong in the temporal area and is
mainly located near the cortical surface. The precise localization of the atrophy is always difficult with a
morphometrical approach but the atrophy patterns are similar to what was already observed in the past for
healthy subjects and AD patients [Hadj-Hamou, 2016].
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(a) Atrophy along the normal aging template trajectory
(b) Atrophy along the disease specific template trajectory
relative volume change (year−1)
Figure 6: Atrophy measured by the divergence of the SVFs parametrizing the two template trajectories.
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These morphological evolutions can be compared to the normal aging model and the mean residual for the
AD subjects in Lorenzi et al. [2015]. The deformation characteristics and the magnitude of the atrophy are
really similar. Our anatomy looks sharper which may be partially explained by the use of the template plane
in the estimation. More importantly, differently from the work of Lorenzi et al. [2015], the joint estimation
of a disease model in addition to the normal aging one provides us with a direct comparison between both
processeses.
The generative model can also be used to directly visualize the modeled morphologies. In particular the
reference template plane T described in Figure 2 can be sampled to shows the evolution of the template
morphology in the two main directions. In Figure 7, we choose to represent the evolution over 20 years in
both directions which is comparable to the longitudinal span of our data-set. Indeed the IQR of baseline
age in the training set is equal to 9.3 years (and the total span is 29.9 years wide). The overlaid difference
of intensity is used to show the changes at tissue boundaries. The global atrophy and the expansion of the
ventricles is clearly visible for the aging evolution. The pathological changes are associated with smaller
structures but the shrinking of the hippocampi, the atrophy of the temporal lobes and also the widening of
the sulci (related to the cortical thickening) are visible.
4.2.2 Intra-subject variability of our progression markers
In Lorenzi et al. [2015], a morphological age similar to our measure was shown to be correlated with the
chronological age and also that advanced AD stages were associated with “morphologically older” brains. To
go further, we want to show that our proposed model represents also the aging at the individual level. For
multiple acquisitions of a same subject, an aging measurement is expected to increase smoothly with time. If
the subject is healthy, we can expect a linear increase with a slope of 1. We would also like to see an increase
of disease score for the patients, while for the healthy subjects this marker should be stable and close to 0.
Therefore, the disease score is expected to specifically characterize the pathology (high and increasing disease
score). The morphological age is expected to be more associated with the global evolution of the population
over time and to be independent of the clinical condition.
The morphological age and the disease score are computed for each subject at each time point. Figure 8
shows the evolution of these cross-sectional measurements. First, at the population level, subjects are gener-
ally associated with a morphological age similar to their chronological age even though its variability is quite
high. Second, for each subject, the evolution is mostly linear and the morphological age steadily increases.
Third, the disease score is almost constant for healthy subjects and steadily increases for the AD subjects.
Finally, we note that the AD subjects look older, age faster and, most of all, have a higher disease score than
the healthy ones.
A linear random effects model can help us to quantify these observations. The model is fitted, for both
morphological age and disease score, with fixed effects on age and sex and a random intercept and slope for
each subject. The focus is set on the analysis of the regression for the CN and the AD groups. For each
coefficient of the regression, the confidence intervals are given for one standard deviation of the estimation.
The model is first fitted to the morphological age measures in the CN group leading to a coefficient of
0.26 ± 0.11 for the fixed effect of age while the mean subject slope is 0.10 ± 0.02. Both are significantly
positive. In comparison to the same model without the random slope the relative improvement brought by
the intra-subject linear evolution is significant by a large margin (p-value inferior to 10−6 for the likelihood
ratio test). The regression has also a positive (but not significantly) coefficient for male subjects (1.81± 1.2)
meaning that male morphologies looks older (similar to a 7 years shift). Concerning the disease score, we
also observe a relatively good fit of the linear model. The evolution is generally slower with 0.12 ± 0.1 for
the fixed effect of age and 0.12± 0.01 for the mean individual slope.
For the AD group, the linear model is also well adapted (p-values inferior to 10−6 for the likelihood ratio
test). The main remark is probably that the intra-subject slopes are in average more important than for
healthy subjects (around 0.52 ± 0.06 for the morphological age and 0.71 ± 0.05 for the disease score) while
the fixed effect related to age of 0.23±0.07 (for the morphological age) and 0.14±0.04 (for the disease score)
are more similar to the one observed previously.
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Figure 7: Representation of the 2D parametric template subspace generated using the template morphology
T0 and the two template trajectories vA (horizontally) and vD (vertically). In this figure, the bottom row
correspond to a healthy evolution, and the diagonal (from bottom left to top right) to a typical pathological
evolution. We also represent the voxel-wise intensity differences between the images and T0 to highlight the
boundary shifts between tissues and CSF.
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Figure 8: Evolution of cross-sectional markers for every subject of the two training sets. [Left] chronological
age, the dashed line corresponds to the expected evolution of healthy subjects i.e. the morphological age is
equal to the chronological age. [Right] disease score, the dashed line is the expected pathological evolution.
4.2.3 Cross-sectional discriminating power
We want to study the relation between the observed disease progression and the proposed markers. We start
with a discriminant analysis using only the first image available for each subject.
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Figure 9: Box-plot of the group-wise markers estimated at baseline for the clinical groups. Stars below the
name of the group indicate a significant difference to the CN- group for a t-test at the level 0.05. Both
markers gradually increase towards more advanced disease states.
Figure 9 shows the distribution of the estimations for each group. These results are related to global
differences in brain shape observable cross-sectionally between clinical groups. We see a gradual increase
of both markers towards more advanced disease states. Significant differences in morphological age and
in disease score are observed between the control group CN-(train) and both the MCIc and AD groups.
Moreover, the difference between the MCI stable and the MCI converters is stronger for the morphological
age while the disease score better differentiates MCIs- and MCIs+. As such, the morphological age is more
associated with the general cognitive degradation while the disease score seems more correlated with more
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AD-specific biomarkers.
We also perform a simple linear classification task between the MCIs and MCIc groups using this two cross-
sectional markers. A SVM linear classifier is fitted to the full data-set to perform the binary classification2.
The error penalty weights are adjusted between the two classes to balance the trade-off between false positive
and false negative rate. The mean classification accuracy using a 10-folds cross-validation scheme is equal
to 0.59. The linear decision function is equivalent to the projection on the SVF vA − 0.003vD, so the
differences between MCIs and MCIc subjects is, in our model, only associated with the aging trajectory
while the disease specific changes do not seem to have an impact before the conversion. For comparison, for
the same experiment between CN and AD, the linear classifier corresponds to the projection on vA + 0.49vD
so approximately (vbn + vad)/2, i.e. the mean evolution of the whole population. Of course, in both cases
we do not reach the performance of state-of-the-art dedicated algorithm but it allows us to see how both
markers are associated with the diagnosis. Moreover this discriminant approach could be extended by using
information in a subset of targeted areas.
4.2.4 Regional analysis of the progression
In the context of Alzheimer’s disease, specific morphological changes are known to be non-uniformly dis-
tributed. This spatial information can be taken into account in our model using a regional segmentation. In
this section we focus on the temporal area which is often associated with Alzheimer’s disease [Double et al.,
1996]. Using the AAL atlas [Tzourio-Mazoyer et al., 2002], we segment the temporal lobe of our template
anatomy. The mask is then used to compute the regional morphological age and disease score for each sub-
ject. These markers only encodes the morphological differences in this specific area visible at the time of
acquisition (i.e. at baseline in this case). Results are shown in Figure 10.
The region is more adapted to the disease score than to the morphological age model. Indeed, for a
healthy subject the deformations in this area are really small. However the choice of a disease-adapted region
is improving the performance of the disease score. It is now able to capture early specific changes and the
difference between CN- and CN+ is significant.
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Figure 10: Box-plot of the markers estimated in the temporal lobes. Stars below the name of the group
indicate a significant difference to the CN- reference for a t-test at the level 0.05. The area known to be
related to the AD makes the disease score estimation less sensitive to the overall noise.
2The classification task was performed using the SVC module of the scikit-learn python library [Pedregosa et al., 2011]
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4.2.5 Longitudinal evolution of the markers
To explore more in details the longitudinal evolution of these markers, a linear model is fitted to the individual
evolutions. The intercept can be interesting as it aggregates the measure at every time point and helps reduce
the noise but more importantly the slope can be very informative. Results are shown in Figure 11 for the
whole brain markers.
A progressive evolution, from CN- to AD, is visible for the morphological age with subjects evolving faster
and faster. Concerning the disease score, the evolution is almost negligible for CN- and MCIs- and relatively
slow for CN+ and MCIs+ while the changes are clearly visible for MCIc and AD. Significant differences
are visible between healthy subjects (CN-) and MCIc or AD subjects or even between MCI stable and MCI
converters, but also between MCIs- and MCIs+ (or more generally between subjects with negative amyloid
or positive amyloid marker). This may indicate that our measures are able to capture the global progression
of the disease. The changes are larger for diagnosed patients but similar patterns of evolution are observed
in the early stages of the disease. A significant difference is also observable between the CN- and CN+ group
for the temporal disease score slope.
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Figure 11: Box-plot of the rate of evolution of the markers computed using individual linear regressions.
Stars indicate a significant difference to the CN- reference for a t-test at the level 0.05. Top row shows the
results for the whole brain while the bottom row shows the result for the temporal lobe only. A gradation is
visible from the CN to the AD subjects.
The disease score evolution is close to zero for the healthy subject and close to one for the pathological
one but more generally, the slopes are in average smaller than their expected values. For example the average
disease score evolution in the AD group is equal to 0.82 and this discrepancy is particularly important for
the morphological age slope of the CN- group that is only equal to 0.33 (instead of 1). This bias was already
observed previously and can be in part explained by the estimation procedure (see 6.2).
4.3 Generating diagnosis driven morphological evolution
One of the main advantages of our model is its ability to be generative. From a pair of biomarkers (mor-
phological age, disease score) we can generate a corresponding morphology and to deform a specific subject
anatomy in the directions defined by the template trajectories. In this section, the model is used to generate
plausible morphological evolutions of a subject, for several diagnosis condition, and compare them to the
observed one.
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4.3.1 Modeling the group evolution
In what follows, each subject is associated with a pair (position, speed) in the marker plane using the coeffi-
cient of the linear regression. For each group, a continuous vector field is regressed from these observations.
This field estimates the local average speed at every point. In order to keep a local consistency in the markers
space, we use a kernel ridge regression with an RBF kernel. The spatial scale is set to 10 years, for both
the morphological age and the disease score axis, to get large scale patterns despite the high inter-subject
variability. The regularization weight, which does not seem to have a large effect on the result, is set to 1.
Results are presented in Figure 12 for the CN (i.e CN-, CN+ together), MCIs, MCIc and AD groups. The
figure is centered on the high data density domain (as expected the extrapolation can be less reliable in lower
density sectors).
Differences in amplitude, i.e. speed of evolution, and orientation are clearly visible between the groups
and are in agreement with the linear regression results shown in the previous section. In particular we see a
progressive amplitude increase from the CN group to the AD group.
These diagrams also help to describe the variability within the same clinical group. For the CN group
we can distinguish between the low disease score and low morphological age area (in the bottom left) where
in average the changes are negligible, and the rest where there is a slow horizontal evolution. This pattern
suggests that the healthier and younger subjects are morphologically stable and do not show the same visible
aging process. The MCI stable evolution is relatively uniform and in average with slightly larger amplitudes
but overall similar to the CN one.
The MCI converters however show a stronger and more vertical evolution. We should also note that
subjects with high morphological age and low disease score (bottom right) seem to follow a different, more
horizontal evolution implying a fast morphological aging but less important disease specific changes. The
AD group confirms this trend and in fact MCIc and AD look very similar. The mean evolution is strong
and more vertical. A main evolution is visible from bottom left to top right with a sightly more horizontal
part in the middle giving this global tangent-like aspect. Beside, a horizontal evolution, similar to what was
observed for the MCIc model, is also visible in the bottom right. This difference of evolution suggests a
possible stratification of the disease in two sub-categories.
4.3.2 Generating a subject specific evolution
The regression model can then be used to simulate the evolution of a given subject. We choose here to
model the evolution of MCIc subject in order to predict the changes subsequently observed around the time
of diagnosis. Several evolutions were computed for the subject 0361. This subject is chosen among the MCIc
subjects because it has the longest time interval, here 8.5 years, between the first and the last acquisition.
From the starting point, the markers at t=0, we integrate a trajectory using the speed given by the regression
model at each point. Each clinical group is associated with its own model and then a different trajectory is
computed for each diagnosis.
These markers changes can be directly translated in brain images to visualize the morphological evolution.
Figure 13 shows the results for the end point of the trajectories for the CN and AD models. Images are
generated by deforming the baseline image using the simulated deformation transported in the subject space.
A bias correction is applied to the markers’ estimation using the value estimated on the synthetic dataset
(the measured changes only correspond to 80% of the expected value).
For both subjects, the cortical atrophy, in particular in the temporal lobe, is clearly visible in the real
image and to a lesser extent in the AD simulation. The expansion of the ventricles is always clearly visible,
but even in the AD simulation, the volume change is inferior to the observation. Subject 0566 is, from the
baseline, generally more atrophied and by comparison it makes some real changes less visible (in particular the
sulci widening). This difference in baseline anatomy is interesting here for two reasons: first the deformations
match correctly the anatomical structures (the hippocampi for example) despite the anatomical variability,
second it generated two different evolutions for the same diagnosis. For the AD simulation, the deformation
seems stronger in the temporal lobe and relatively weaker in the ventricles for the second case (0556). These
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Figure 12: Results of the kernel ridge regression for the markers’ evolution for the CN, MCIs, MCIc and
AD groups. It shows the regressed vector field with data points shown in red. Amplitude and orientation
variability is visible between the groups (with stronger and more vertical evolution for AD than for CN) but
also within each group giving non-linear morphological evolutions.
evolutions are learned from population trends and even if they are not predictive for a particular subject,
they are not aberrant in comparison with the real evolutions. Overall, the morphological changes simulated
looks realistic even if they do not match perfectly the observed changes. Other aspects of the evolution are
hard to quantify and often poorly documented. For example the evolution of the shape of the ventricles
of subject 0361 is different in the three images. It may be related to different spatial distribution of the
degeneration in the brain and inherent mechanical constraints. We also observe a global motion towards the
bottom of the temporal lobe and a local rotation in the image for the real case and the AD simulation.
5 Discussion and perspectives
In this work, we proposed a novel deformation-based approach to measure the progression of normal and
pathological processes from their effects on brain morphology. In the context of Alzheimer’s disease, it
provides a simple description of the brain morphological evolution for elderly patients using only two degrees
of freedom: an aging measurement and a disease score. The advantages come from three main properties.
First, we disentangle the aging and the disease progression using interpretable image-based biomarkers.
Second, these markers are cross-sectional assessments and are consistent for intra-subject longitudinal anal-
yses. They can be seen as alternative aging measurements compatible with ongoing biological processes.
In particular the disease specific evolution appears to be associated with a positive amyloid marker even in
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Figure 13: Evolution of the two subjects over 8.5 years. Both subjects were diagnosed MCI (for 5y and
3y) then AD. From left to right: (1) real image at baseline, (2) simulated image from the baseline image
using the healthy (CN) evolution, (3) using the pathological (AD) evolution, (4) real image at t=8.5y. The
second row zooms in the most interesting areas between the ventricle (A), the lateral sulcus (B) and the
hippocampus area (C). In both cases, even if the simulated changes do not match the full extend of the real
case, the atrophy is visible in the sulcus and the hippocampus and there is a difference in shape and size of
the ventricles.
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prodromal stages. Third, we show that the markers and the generative model can be used in a personal-
ized image simulation setting. It allows us to generate smooth and realistic evolutions for several diagnosis
conditions.
Biological (or here morphological) age estimates were proven to be interesting to analyze the patient
condition; here, in addition, the disease score is used to get a simple marker of the disease progression. The
joint modeling gives a more complete description of the disease progression than a brain-age metric. The
evolution is not seen as a simple accelerated aging process or the divergence from the normal evolution.
On the contrary, it seems possible to capture the general worsening with the morphological age while the
disease score measures an additional evolution that is more specific to the disease. Both patterns of evolution
appeared to be related with the development of Alzheimer’s disease and this approach provides an intuitive
interpretation and a simple decomposition of the morphological changes observed in mass-univariate mor-
phometric approaches. Further analysis should be conducted to analyze the relation of these complementary
patterns to clinical and cognitive variables.
Moreover the ideas behind the decomposition and the longitudinal/cross-sectional estimation of the pa-
rameters could be used in a different setting: the geodesic description is much more general than the SVF
framework applied to structural MRIs. Other geodesic parametrizations could be more practical in another
setting and even for the same image data, an LDDMM approach, for example, would generally concentrate
the deformation more on the high intensity gradient interfaces while the SVFs model more spatially diffuse
deformations.
Several approaches have been developed to model the longitudinal shape evolution using geodesic mod-
eling [Singh et al., 2013]. Here we suggest that decoupling the estimation of individual trends using parallel
transport could allow a more accurate and non-linear description of the disease while keeping a similar
hierarchical mixed-effect structure.
As could be expected, a single variable is not enough to precisely describe the morphological changes
that can occur while aging. Likewise, the inter-subject variability limits the accuracy of the modeling of
the evolution of individual subjects. Some limitations come from the error and the approximation in the
estimation of the model, others are related to aspects that are not taken into account and would require to
modify the approach.
5.1 Approximations in the model estimation
One of the limitations of our approach is the difficulty to accurately estimate the markers. For example,
some time points look like outliers when we perform the estimation for successive images of the same subject.
This might be due to MR distortions that cannot be completely corrected by the registration. As a result,
some artifacts are still visible in the estimated deformations. A better understanding of the effects of these
distortions on the registration results would be useful to improve our additive deformation noise model. A
first step could be to work with data where the ground-truth deformation is more controlled (scan-rescan
images for example).
In this work, we used an orthogonal projection using the L2 scalar product in the SVF space to define
the subject specific deformation. This choice is arbitrary and using another region of interest could change
the result. A possible alternative would be to match the subject with the closest morphology in the model
for a metric more adapted to deformations. We could also try to decorrelate the two information, using ICA
for example.
We saw, using synthetic and longitudinal data, that we were under-estimating the evolution speed. This
bias is partially explained by the estimation procedure that does not take into account the uncertainty on
the population parameters of the model (see 6.2). This problem cannot be easily solved for two reasons:
first the bias caused by the estimation of the template anatomy using the healthy controls groups is hard to
quantify, second an unbiased estimation would be far more complex and would not be possible without the full
knowledge of the training set for every new subject. Another source of error can be the registration algorithm:
the inter-subject registrations are larger than the intra-subject ones and no transitivity is guaranteed.
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5.2 Limitations of the description
Probably the main limitation of our approach is the inter-subject variability of the markers. The markers
are very stable in longitudinal but the anatomical variability is not completely absorbed by the biomarker
estimation and they are sensitive to the subject differences. The use of an explicit or even implicit model of
the shape of a normal brain would help to makes them more specific to time related changes.
We could also note that the template anatomy is estimated using healthy subjects only. This modeling
choice may introduce a bias towards the healthy population. We argue that the explicit modeling of the disease
in our model could help mitigating this issue. Moreover, this choice makes the origin of the morphological
age and the disease score simpler to define. Finally, pulling all the subjects could also enable a more accurate
estimation [Marchewka et al., 2014] but the relatively large and homogeneous populations involved does not
make it critical here.
In this context, the use of a single reference anatomy to parametrize the template space could also be
discussed. Here, for example, it introduced a bias toward a certain age because of the way we composed
deformations. A multi-atlas approach could be a better solution if a single anatomy is not enough to describe
our population [Blezek and Miller, 2007, Sabuncu et al., 2009]. And we could do something similar to what
was proposed by Rohé et al. [2016] to intricate the registration and the template subspace prior.
Regarding the estimation of the template trajectories using individual longitudinal SVFs transported in
the template, potential bias associated with the asymmetrical use of the baseline image (in processing and
in modeling) has been highlighted [Reuter et al., 2012] and the imbalance in number of time points or total
longitudinal span should be taken into account for a more reliable estimation. However, Hadj-Hamou et al.
[2016] has shown that the asymmetry caused by the non centrality of the time point in the longitudinal
sequence is not completely relevant in the stationary velocity field framework because the SVF are expressed
in Eulerian coordinate and should be identical at all time points.
5.3 Perspectives
The use of segmentation to compute the progression markers in multiple regions would be another way
to extend the description. We showed that using a segmentation of the temporal lobes could tighten the
link between the morphological markers and early clinical conditions. However the question of the regional
interactions is not addressed in this work and the spatial analysis of brain deformation remains a research
topic.
Our model of the morphological evolution is generic and of low dimensionality. Consequently it only
partially captures the changes related to AD and, in practice, the subject specific field wkr is actually encod-
ing changes that are related to the disease and its variability but are not currently modeled. To enhance
the description, the model should integrate the observed and latent clinical condition of the subjects. A
description that goes beyond the global cognitive diagnosis would be interesting to pursue in the temporal
description of the morphological changes in order to better describe the disease progression and capture this
evolution from a healthy state to a pathological one.
Beside, the observed longitudinal evolution is also influenced by various factors such as sex, genetic, other
pathologies or even the image acquisition protocol. The ability to handles these covariates has shown its
utility to better describe the brain morphological evolution [Muralidharan et al., 2016].
These extensions would also improve the generative aspect. Coupling our approach with a proper disease
progression model, and using a mixture model for the trajectories, would enable the generation of morpho-
logical trajectories in a more diverse setting to explore and sample the range of possible evolutions.
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6 Appendix
6.1 Validation on a synthetic dataset
The regional values of atrophy set are given in Table 2. For each subject, the values are sampled around
these means with a 5% standard deviation.
brain area mean pathological (in %) mean healthy (in %)
white matter 1.0 0.8
cortex 3.0 0.4
hippocampi 5.2 1.0
amygdalae 5.2 1.0
entorhinal cortex 6.5 0.7
temporal poles 6.2 0.6
other areas 0.0 0.0
Table 2: Specified mean regional atrophy for the healthy and the pathological evolutions. The goal is to get
simple but realistic atrophy patterns. It should be noted that the atrophy is specified using the divergence
of the SVF in the area. The local volume changes are computed using a spatio-temporal integration scheme.
The comparison with the values obtained after simulation or estimated through registration are shown in
Figure 14. The estimation can be biased by the spatial regularization and the loss of information in intensity
homogeneous areas. The relative changes is however similar between the two populations and the method is
by consequence adapted to compare the two evolutions.
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Figure 14: Comparison of prescribed, simulated and estimated atrophy values for several brain regions.
The difference between prescription and simulation can be explained by numerical approximations in the
biophysical model while the estimation is biased due to spatial regularization. However the estimation bias
is consistent accross regions and subjects.
6.2 Bias on the estimated template trajectories
The norms of the SVFs parametrizing the template trajectories have an effect on the normalization of the
individual biomarkers estimation. We estimate here the bias on the the norm of the estimation relatively to
the estimated norm.
For the normal aging trajectory we have:
E(‖vˆA‖2) = 1|Gh|2E(<
∑
k∈Gh
vk|
∑
k∈Gh
vk >)
=
1
|Gh|2
∑
i,j∈Gh
E(< siMAvA + s
i
DSvD + v
i
r|sjMAvA + sjDSvD + vjr >)
=
1
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∑
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E(siMAs
j
MA)‖vA‖2 + E(siDSsjDS)‖vD‖2 + E(siMAsjDS + siDSsjMA) < vA|vD > +E(< vir|vjr >)
Assuming that the subjects are independent and identically distributed:
E(‖vˆA‖2) = ‖vA‖2 + 1|Gh|2
∑
i∈Gh
Var(siMA)‖vA‖2 + Var(siDS)‖vD‖2 + 2E(siMAsiDS) < vA|vD > +E(‖vir‖2)
=
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And similarly for ‖vˆD‖:
E(‖vˆD‖2) = E
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The terms Var(sMA), Var(sDS) and ‖vr‖2 are related to the individual variability that is not modeled and
to the noise in the estimated deformations. We empirically estimate the variances in the training population
and we get that, for our training dataset, ‖vˆA‖2 ≈ 1.65‖vA‖2 and ‖vˆD‖2 ≈ 1.21‖vD‖2. We should however
note that the same subjects from Gh are used to estimate the template anatomy T0 and the normal aging
template trajectory vA. Therefore, we are certainly underestimating the bias coming from the intra-subject
morphological variability for this population.
This bias has a direct influence on the markers estimations. Indeed for a subject k, the markers are
solution of the linear system 9 involving ‖vA‖2, ‖vD‖2 for which the biased estimators are used.
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